The article talks about the treatment of Bipolar Disorder (BD) treated using a number of medications chief of which is Lurasidone. Lurasidone is administered to patients suffering from BD and other conditions such as Major Depressive Disorder. Fornaro et al. provide that treatment of this disorder is risky as the condition is characterized by both mania and depression. These two conditions further, require careful consideration in terms of administering medication as treating one with certain medicines may cause an adverse reaction on the other (2017). The modality used is by way of evidence-based treatment which is focused on finding the right diagnosis of the myriad of conditions closely related, a treatment which may include administration of medication and eventual follow up.
Much emphases is given on the knowledge and skills attained by doctors and nurses. This is because this knowledge is essential in ensuring that a patient is treated accordingly and advice is imparted wisely. Nurses are entrusted with the mandate of ensuring that patients have the best care that can be afforded to them which includes aftercare, monitoring and follow up. Relapse prevention is an approach taken to prevent relapse and those situations that may trigger one. Research undertaken holds that Lurasidone is more effective in preventing relapse while compared to the other medicines (Fornaro, 2017).
The article is significant in providing the evidence-based results as being ahead of other medications such as Quetiapine and OFC. It provides that Lurasidone is more effective in preventing relapse, maintaining weight gain and mitigating the depression symptoms. The article further highlights the challenges observed in treating these symptoms by underscoring the similarities of Bipolar Disorder with other conditions such as MDD. There is a need, therefore, for proper diagnosis in the first instance in order to prevent fatalities due to misdiagnosis. Furthermore, the Food and Drug Administration (FDA) agency gave Lurasidone an approval for administration to patients with BD in 2013. Despite this, more tests and studies are being done on the efficacy of the drug by taking empirical measures and methodologies (Citrome, 2012). These studies are aimed at providing more evidence in order to ensure safety in administering the drug. The dug has further been approved for other conditions such as schizophrenia; these provide more reason for these feasibility studies.
The review carried out was able to show many data on the composition of the drug and its improvements. Additionally, studies carried out sought to provide an actual measurement to the side effects experienced by the administration of the drug (). The article highlights the improvements and reaps gained by Lurasidone when it comes to side effects. Compared to other drugs, the side effects shown are milder and consist of nausea, akathisia, and sedation. These results are a direct result of the empirical studies undertaken. The study further finds that there is a thin line between helping and harming and it is all in the administration of the drug (Citrome, 2012). Nurses must, therefore, be provided with constant education and learning opportunities to enable them to work effectively.
The review provides a comparative study of Lurasidone and other drugs under the same classification. The article further highlights the process undertaken to acquire approval from the FDA. It further provides the additional studies and tests undertaken despite the approval. The study is significant as BD has become a common condition in people and its difficulties in treating it highlight the need for research, education impacting and studies in this field.
Citrome, L. (2012) Lurasidone for the Acute Treatment of Adults with Schizophrenia: What is the Number Needed to Treat, Number needed to harm, and Likelihood to be helped or Harmed? Clinical Schizophrenia and Related Psychoses, pp. 1-7.
Fornaro, M., Berardis, D., Perna, G., Solmi, M., Veronese, N., Orsolini, L. … de Bartolomeis, A. (2017). Lurasidone in the treatment of bipolar depression. Systematic reviews of systematic reviews. Biomedical Research International, 2017, 1-17.
Loebel, A., Xu, J., Hsu, J., Cucchiaro, J. and Pikalov, A. (2014) the Development of Lurasidone for Bipolar Depression, Annals of the New York Academy of Sciences, pp. 95-104.